MA52894A - 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci - Google Patents

19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci

Info

Publication number
MA52894A
MA52894A MA052894A MA52894A MA52894A MA 52894 A MA52894 A MA 52894A MA 052894 A MA052894 A MA 052894A MA 52894 A MA52894 A MA 52894A MA 52894 A MA52894 A MA 52894A
Authority
MA
Morocco
Prior art keywords
disubstituted
steroid
pyrazolyl
methods
same
Prior art date
Application number
MA052894A
Other languages
English (en)
Inventor
James J Doherty
Handan Gunduz-Bruce
Jeffrey M Jonas
Stephen Jay Kanes
Robert Alfonso Lasser
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MA52894A publication Critical patent/MA52894A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052894A 2018-06-12 2019-06-12 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci MA52894A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684155P 2018-06-12 2018-06-12
US201962789329P 2019-01-07 2019-01-07
US201962841645P 2019-05-01 2019-05-01

Publications (1)

Publication Number Publication Date
MA52894A true MA52894A (fr) 2021-04-21

Family

ID=67211854

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052894A MA52894A (fr) 2018-06-12 2019-06-12 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci

Country Status (12)

Country Link
US (4) US20210338692A1 (fr)
EP (1) EP3806863A1 (fr)
JP (3) JP2021527092A (fr)
KR (1) KR20210021005A (fr)
CN (2) CN117959309A (fr)
AU (2) AU2019287491B2 (fr)
CA (1) CA3103421A1 (fr)
IL (1) IL279315A (fr)
MA (1) MA52894A (fr)
MX (2) MX2020013557A (fr)
SG (1) SG11202012344RA (fr)
WO (1) WO2019241442A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
CN113527400B (zh) 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
WO2015195962A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03749B (fr) 2014-11-27 2021-04-20 Sage Therapeutics Inc Compositions et procédés pour traiter des troubles du snc
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
AU2020395246A1 (en) * 2019-12-05 2022-06-16 Sage Therapeutics, Inc. A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
BR112023000990A2 (pt) * 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
US20240122945A1 (en) * 2021-01-28 2024-04-18 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
US20240245711A1 (en) * 2021-03-17 2024-07-25 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
TW202308654A (zh) * 2021-04-29 2023-03-01 美商賽吉醫療公司 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法
CA3217866A1 (fr) * 2021-04-29 2022-11-03 Sage Therapeutics, Inc. Steroide neuroactif destine a etre utilise dans le traitement d'un trouble depressif majeur et de la depression post-partum chez une femme allaitante
KR20240148425A (ko) * 2022-02-16 2024-10-11 세이지 테라퓨틱스, 인크. Cns-관련 장애의 치료를 위한 신경활성 스테로이드
WO2025175214A1 (fr) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Méthodes de traitement d'un trouble d'anxiété généralisée

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527400B (zh) * 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SMT202000414T1 (it) * 2014-10-16 2020-09-10 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
RU2766155C2 (ru) * 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
CN115974956A (zh) * 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
CA3075038A1 (fr) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. Steroides neuroactifs et leurs methodes d'utilisation

Also Published As

Publication number Publication date
AU2019287491B2 (en) 2025-05-15
US20220323462A1 (en) 2022-10-13
EP3806863A1 (fr) 2021-04-21
MX2025000166A (es) 2025-03-07
US20210338692A1 (en) 2021-11-04
JP2021527092A (ja) 2021-10-11
IL279315A (en) 2021-01-31
JP2025108553A (ja) 2025-07-23
AU2019287491A1 (en) 2021-01-07
AU2025217363A1 (en) 2025-09-04
SG11202012344RA (en) 2021-01-28
US20200113917A1 (en) 2020-04-16
MX2020013557A (es) 2021-05-27
CA3103421A1 (fr) 2019-12-19
CN117959309A (zh) 2024-05-03
CN112533611A (zh) 2021-03-19
US20250339447A1 (en) 2025-11-06
WO2019241442A1 (fr) 2019-12-19
KR20210021005A (ko) 2021-02-24
TW202005653A (zh) 2020-02-01
JP2024028849A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA45599A (fr) Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3950716A4 (fr) Anticorps anti-claudine 18.2 et utilisation associée
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3878863A4 (fr) Anticorps anti-claudin18.2 et son utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
IL279315A (en) 19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using it
EP3495391A4 (fr) Anticorps dirigé contre le ligand 1 de mort programmée (pd-l1) et son utilisation
EP4054765A4 (fr) Systèmes microfluidiques numériques, appareils et procédés d'utilisation de ceux-ci
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3746211A4 (fr) Dispositifs, procédés et kits de caractérisation d'échantillon
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3707158A4 (fr) Biomarqueurs du cancer et leurs procédés d'utilisation
EP3757563A4 (fr) Procédé, dispositif et programme de test ultrasonore, et système de test ultrasonore
EP3801574A4 (fr) Procédés d'édition génomique et d'activation de cellules
EP3807348A4 (fr) Gels cellulosiques, films et composites comprenant les gels, et procédés de formation de ceux-ci
EP3621660A4 (fr) Compositions et procédés d'utilisation de capsides arc
IL278926A (en) Antibodies specific to CD3 and their uses
MA52416A (fr) Anticorps b7-h4 et leurs procédés d'utilisation
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
EP3464346A4 (fr) Anticorps, composition et kits les comprenant et leurs procédés d'utilisation
MA50516A (fr) Anticorps anti-apoc3 et leurs procédés d'utilisation